ONCOLOGY INST. A DL-,0001 Aktie

ALX Oncology presented preclinical data and the study design for the EGFR‑targeted ADC candidate ALX2004 at AACR‑NCI‑EORTC 2025. The phase‑1 first‑in‑human study began in August; initial safety data are expected in H1 2026. ALX2004 uses an antibody derived from Matuzumab and an improved linker‑payload platform to reduce skin toxicity and enhance bystander effects. The company reports a strong liquidity position; investors will watch study progress, cash burn and the quarterly report on 6 November. » More on de.investing.com

ALX Oncology has appointed Dr. Barbara Klencke as interim chief medical officer; she will resign her supervisory board mandate to take the role. The previous CMO, Dr. Alan Sandler, is returning to his former supervisory board seat. The company, with a market valuation of about USD 63 million and a high cash burn rate, reported Q2/2025 EPS of -0.49 USD, missing expectations. In parallel, ALX launched a phase‑1 study of the antibody‑drug conjugate ALX2004, while the clinical development of Evorpacept continues. » More on de.investing.com

ALX Oncology Holdings Inc. has treated the first patient in the phase-1 study of its EGFR-targeting antibody-drug conjugate and expects initial safety data in the first half of 2026. The company shows a strong liquidity position (current ratio 4.52), but missed analysts' expectations in Q2 2025 with EPS of -$0.49. The stock recently showed strong price momentum with a roughly 58% weekly gain. » More on de.investing.com